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ABSTRACT
In the present study, we found that selective inhibition of histone deacetylase 
2 (HDAC2) with small inhibitory RNA (siRNA) induced survivin downregulation in 
a p53-dependent manner. Interestingly, suberoylanilide hydroxamic acid (SAHA) 
or knockdown of HDAC2 induced downregulation of Mdm2, a negative regulator of 
p53, at the protein level. SAHA and/or HDAC2 siRNA increased Mdm2 ubiquitination, 
and MG132, an inhibitor of proteosome function, prevented HDAC2 inhibition-
induced degradation of Mdm2. Clinically, the mRNA levels of HDAC2 and survivin 
were prominently overexpressed in lung cancer patients compared to normal lung 
tissues. Silencing of HDAC2 enhanced the cell death caused by ionizing radiation in 
lung cancer cells. Collectively, our results indicate that selective inhibition of HDAC2 
causes survivin downregulation through activation of p53, which is mediated by 
downregulation of Mdm2. They further suggest that HDAC2 may exert a dominant 
effect on lung cancer cell survival by sustaining Mdm2-survivin levels.
INTRODUCTION
Members of the histone deacetylase (HDAC) 
family, encoded by 18 distinct genes, are divided into 
four classes—class I, class IIa, class IIb, class III and 
class IV—based on their homology. HDACs catalyze the 
removal of acetyl groups from lysine residues located on 
amino terminal tails of histone protein [1]. By controlling 
the level of acetylation of core histones, HDACs are 
generally associated with repression of transcription and 
reduced gene expression [2]. In addition to interacting with 
chromatin proteins, HDACs can lead to altered expression 
of a large number of genes through direct interaction with 
non-histone proteins, such as the transcription factors E2F 
and Stat3, and the tumor-suppressor p53 [3, 4]. Several 
Oncotarget26529www.impactjournals.com/oncotarget
studies have shown that class I and II HDACs (HDAC1-
10) are overexpressed in some cancers, including gastric 
cancer, colorectal cancer, prostate cancer, and lung cancer 
[5, 6]. Moreover, both altered expression and mutation 
of HDACs have been linked to cancer formation and 
progression, reflecting the fact that these changes in 
HDACs induce aberrant transcription of key genes that 
regulate important cellular functions [2]. In light of this, 
class I and II HDACs have emerged as attractive targets for 
anticancer therapy. In fact, two recently developed HDAC 
inhibitors—vorinostat (suberoylanilide hydroxamic 
acid (SAHA), Zolinza) and depsipeptide (romidepsin, 
Istodax)—have been approved by the US Food and Drug 
Administration (FDA) as anticancer drugs [1, 7]. HDAC 
inhibitors have been shown to induce apoptotic cell death 
and growth arrest in various cancer cells, promote reactive 
oxygen species generation, and inhibit angiogenesis 
through downregulation of genes involved in regulating 
angiogenesis, including hypoxia-inducible factor 1 alpha 
(HIF1α) and vascular endothelial growth factor (VEGF) 
[8]. Suberoylanilide hydroxamic acid (SAHA) has been 
shown to enhance radiosensitivity in preclinical tumor 
models [9]. SAHA treatment in combination with ionizing 
radiation has been reported to attenuate the upregulation 
of DNA damage-repair proteins, including DNA-activated 
protein kinase (DNA-PK) and the recombinase Rad51 
[10]. Although HDAC inhibitors have been evaluated in 
clinical trials, the different and specific roles of individual 
HDACs in carcinogenesis remain unclear. 
Survivin, a member of the inhibitor of apoptosis 
family, is undetectable in most normal adult cells but 
is frequently overexpressed in a variety of cancer cells. 
It has been shown that survivin inhibits apoptosis, 
promotes tumor-associated angiogenesis, and serves as a 
determinant of resistance to various anticancer therapies 
[11]. Survivin expression inhibits cell death induced 
by various apoptotic stimuli in vitro and in vivo [12]. 
Notably, overexpression of survivin is detected in early-
stage non-small-cell lung cancer patients, suggesting 
that survivin may play a role in lung tumorigenesis [13]. 
It has also been reported that survivin gene expression 
is transcriptionally repressed by wild-type p53, which 
binds directly to the survivin promoter [14, 15]. As a 
downstream factor that is highly expressed in cancer 
and regulated by p53, survivin is a dual mediator of 
resistance to apoptosis and cell-cycle progression [16]. 
Thus, regulation of the p53-survivin signaling pathway 
is important for cell survival. We previously showed that 
SAHA is a potential therapeutic agent by virtue of its 
downregulation of survivin in lung cancer [17]. HDAC 
inhibitors have been shown to induce cell death by 
suppressing survivin expression in various cancer cells, 
including non-small cell lung cancer (NSCLC), renal cell 
carcinoma and epidermoid carcinoma [18-22]. A better 
understanding of the molecular mechanism underlying the 
regulation of survivin expression by specific members of 
the HDAC subfamily and the role of p53 in this process 
could provide a novel strategy for minimizing toxicity and 
acquiring high efficacy through targeting of survivin. 
In the present study, we investigated the role of 
individual HDACs in regulating survivin expression. We 
further explored possible molecular mechanism(s) by 
which inhibition of HDAC2 negatively regulates survivin 
expression and elucidated the relationship between 
inhibition of HDAC2 and radiosensitivity in non-small-
cell lung cancer cells. We found that inhibition of HDACs 
with a chemical inhibitor or genetic knockdown of 
HDAC2 downregulated survivin by increasing p53 protein 
stability. Interestingly, the increase in p53 protein induced 
by HDAC2 knockdown was mediated by proteosomal 
degradation of the p53 negative regulator, Mdm2. 
Together, these findings suggest that HDAC2 might be an 
important molecular player in the regulation of Mdm2 and 
survivin expression levels in lung cancer cells.
RESULTS
SAHA induces survivin downregulation through 
p53 activation
In our previous report, we examined the effect 
of SAHA on the expression of survivin in human non-
small-cell lung cancer cells [17]. We found that SAHA 
decreased the expression of survivin. Here, we confirmed 
that SAHA induced a concentration-dependent decrease in 
survivin levels in A549 cells; it also increased acetyl-p53, 
p21, puma and acetyl-histone levels without expression 
changes of HDACs (Fig. 1A). RT-PCR analyses showed 
that survivin mRNA levels were also downregulated by 
treatment with SAHA for 24 h (Fig. 1B). These results 
suggest that SAHA regulates survivin expression at the 
transcriptional level.
To further investigate whether p53 is associated 
with SAHA-induced downregulation of survivin, we 
examined survivin expression in p53 wild-type A549 cells 
and p53-null H1299 cells after treatment with SAHA. 
SAHA decreased survivin protein levels in A549 cells, 
but did not affect survivin levels in H1299 cells (Fig. 1C). 
Furthermore, knockdown of p53 with siRNA significantly 
attenuated the reduction in survivin protein levels 
induced by SAHA in A549 cells (Fig. 1D). In H1299 
cells transfected with a p53 expression plasmid, SAHA 
treatment resulted in downregulation of survivin (Fig. 1E). 
We examined the level of survivin using Western blotting 
in HCT116 colon cancer cell lines, p53(-/-) and p53(+/+) 
after treatment with SAHA. In Fig.1F, basal survivin level 
in p53(+/+) cell line are lower than p53(-/-) cell line. p53 
expression was increased and survivin expression was 
decreased by SAHA in p53(+/+) cell line, but SAHA did 
not affect survivin levels in p53(-/-) cells. Transfection of 
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Figure 1: SAHA-induced survivin downregulation by p53 activation. After incubation, cells were lysed and analyzed by 
Western blotting and RT-PCR as described in Materials and Methods. β-actin was used as a control for equal protein and cDNA loading. In 
qPCR, Survivin mRNA expression levels were determined by the relative to the control groups using 2-ΔΔCt method. Values were represented 
as means ± SD of three independent experiments. Immunoblots and PCR bands are representative of at least three independent experiments. 
A. A549 cells were treated with 0–3 μM SAHA for 24 h. B. A549 cells were treated with 3 μM SAHA for various times (RT-PCR) or for 24 
h (qPCR). C. A549 and H1299 cells were treated with 2 μM SAHA for 24 h. D. A549 cells were transfected with 50 nM p53 siRNA (si p53) 
or negative control siRNA (si CTL) and were treated with 2 μM SAHA (+) for 24 h. E. H1299 cells were transfected with 0.1 μg p53 wild-
type expression plasmid (p53) or empty vector (pCMV) using Lipofectamine and treated with 2 μM SAHA for 24 h. The specificity of p53 
interference or overexpression was confirmed using an anti-p53 antibody. F. HCT 116 colon cancer cell lines, p53(-/-) and p53(+/+) were 
treated with 2 μM SAHA (+) for 24 h. G. A549 cells were transfected with 0.1 μg p53 wild-type expression plasmid (p53), p53 dominant 
negative expression plasmid (C135Y, 135C to Y mutation) or empty vector (pCMV) and treated with 2 μM SAHA for 24 h.
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A549 p53-wild cells with a plasmid expressing the p53 
C135Y mutant (C135Y) led to recovery survivin down-
regulation induced by SAHA (Fig. 1G). The p53 C135Y 
expression plasmid encoding a dominant-negative mutant 
can no longer interact with p53 binding sites because of a 
conformational change induced by mutation of cysteine 
135 to tyrosine [24]. Collectively, these results indicate the 
p53 activation plays an important role in SAHA-induced 
survivin downregulation. 
Selective inhibition of HDAC2 induces survivin 
downregulation 
To identify the role of individual HDACs in survivin 
expression, we transiently transfected A549 cells with 
siRNA individually targeting the HDAC family members, 
HDAC1, HDAC2, HDAC3, and HDAC4. Western blot 
analyses showed that each selective siRNA specifically 
decreased the protein level of its targeted HDAC. 
Interestingly, we found that knockdown of HDAC2 
changed survivin and p53 protein levels prominently (Fig. 
2A). 
Next, we tested the role of p53 in HDAC2 siRNA-
mediated downregulation of survivin in p53 wild-
type A549 lung cancer cells. HDAC2 siRNA induced 
an increase in p53 protein levels and corresponding 
reduction in survivin protein levels dose-dependently as 
well as survivin mRNA levels (Fig. 2B). When we used 
two different HDAC2 siRNAs, the effect on survivin 
was in same manner with Fig 2B. (Fig. 2C) Furthermore, 
knockdown of p53 with siRNA significantly reversed the 
HDAC2 siRNA-induced reduction in survivin protein 
(Fig. 2D). These results indicate that HDAC2, among 
HDAC isoforms, specifically plays a role on regulation 
of survivin and p53 acts as a mediator of HDAC2 
knockdown-induced survivin downregulation. 
HDAC2 inhibition induces Mdm2 downregulation 
through proteasomal degradation
To identify the molecular mechanism(s) underlying 
the activation of p53 induced by SAHA or knockdown 
of HDAC2, we investigated Mdm2 levels after treatment 
with SAHA or siRNA targeting HDAC2 in A549 lung 
cancer cells. Unexpectedly, we found that SAHA induced 
a concentration-dependent decrease in Mdm2 protein 
levels (Fig. 3A). In Fig. 3B, 3C and 3D, HDAC2 siRNA 
similarly induced a marked, dose-dependent decrease 
in Mdm2 levels; in contrast, siRNA targeting HDAC1 
or -3 had no such an effect. To investigate the possible 
mechanism responsible for SAHA-induced Mdm2 
downregulation, we first performed RT-PCR to test the 
expression of Mdm2 mRNA in SAHA or HDAC2 siRNA-
treated cells. Nutlin-3A, used as positive control for 
Mdm2 mRNA regulation [25], markedly increased Mdm2 
mRNA levels, whereas SAHA or HDAC2 siRNA had no 
effect on Mdm2 mRNA levels (Fig. 3E and 3F). 
These results suggest that Mdm2 is downregulated 
at the protein level by SAHA. To verify this, we examined 
SAHA or HDAC2 siRNA effects on Mdm2 protein 
expression in cells treated with the proteasome inhibitor, 
MG132. As shown in Fig.4A and 4B, Mdm2 expression 
levels were restored in cells co-treated with SAHA or 
HDAC2 siRNA and MG132. Furthermore, ubiquitination 
assays confirmed that Mdm2 was ubiquitinated after 
treatment with SAHA and/or HDAC2 siRNA (Fig. 4C 
and 4D). These results strongly suggest that inhibition of 
HDAC2 induces p53-dependent survivin downregulation 
through proteasome-mediated degradation of Mdm2.
Correlation between HDAC2 and survivin 
expression in lung cancer cell lines and 
overexpression of HDAC2 and survivin in lung 
cancer patients
To determine whether HDAC2 and survivin 
expression are correlated in lung cancer cell lines, we 
analyzed the expression of HDAC2 and survivin at the 
protein level in A549, H460 and Lu99 cell lines (non-
small lung cancer cell, p53 wild type). As shown in 
Fig.5A, survivin expression levels in lung cancer cell 
lines were highly correlated with HDAC2 expression 
levels. SIRT1 and SIRT2 are classified to HDAC Class 
III, and are not inhibited by SAHA. One of the non-
histone target of SIRT1, p53, is suggested to play a central 
mediator of SIRT1-mediated functions in the process of 
tumorigenesis and senescence. Furthermore, there are 
new evidences that SIRT1 acts as a tumor suppressor 
based on its role in negatively regulating beta-catenin and 
survivin. [26] Therefore, we detected SIRT1 and 2 levels 
as well as HDAC1-4 in lung cancer cell lines and then 
confirmed that HDAC2 expression are related to survivin 
regardless of SIRT1 and SIRT2. Comparison of HDAC2 
and survivin mRNA expression levels between normal 
and cancer were performed using TissueScan Cancer 
Array (each containing cDNAs from 8 different normal 
lung and 40 lung cancer patient tissues). In lung cancer 
patients, survivin and HDAC2 mRNA expression were 
overexpressed compared to normal lung tissues (Fig 5B). 
These results indicate that expression of survivin may be 
regulated by HDAC2 in lung cancer cells.
Knockdown of HDAC2 enhances sensitivity to IR-
induced cell death
Since IR can induce cell death in p53-dependent 
manner [24, 27], we next determined whether HDAC2 
siRNA enhanced the sensitivity of lung cancer cells to IR-
induced cell death. As shown in Fig.6A, HDAC2 siRNA 
markedly enhanced the sensitivity of cells to IR-induced 
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Figure 2: Suppression of survivin expression by HDAC2 siRNA. After incubation, cells were lysed and analyzed by Western 
blotting and qPCR. β-actin was used as a control for equal protein loading. In qPCR, Survivin mRNA expression levels were determined 
by the relative to the control groups using 2-ΔΔCt method. Values were represented as means ± SD of three independent experiments. 
Immunoblots are representative of at least three independent experiments. A. A549 cells were transfected with 50 nM siRNA targeting 
specific HDAC isoforms (si HDAC1, si HDAC2, si HDAC3, si HDAC4) or negative control siRNA (si CTL) and incubated for 24 h. The 
relative protein level of p53 and survivin are presented by the graph of the quantitative values. B. A549 cells were transfected with 60 or 
120 nM HDAC2 siRNA or control siRNA and incubated for 24 h. (Western blotting) and cells were transfected with 60 nM HDAC2 siRNA 
(+) or control siRNA (-) and incubated for 24 h. (qPCR) C. A549 cell were transfected with two different HDAC2 siRNA (60 nM) for 24h. 
D. A549 cells were transfected with 50 nM p53 siRNA and 60 nM HDAC2 siRNA, alone or in combination, and incubated for 24 h. 
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Figure 3: Mdm2 downregulation by SAHA or HDAC2 siRNA. After incubation, cells were lysed and analyzed by Western blotting 
and RT-PCR. β-actin was used as a control for equal protein and cDNA loading. In qPCR, mRNA expression levels were determined by the 
relative to the control groups using 2-ΔΔCt method. Values were represented as means ± SD of three independent experiments. Immunoblots 
and PCR bands are representative of at least three independent experiments. A. A549 cells were treated as described for Figure 1A. B. 
A549 cells were transfected with 60 nM siRNA targeting specific HDACs (HDAC1, HDAC2, HDAC3) or negative control siRNA, and 
then treated with 2 μM SAHA for 24 h. C. A549 cells were treated as described for Figure 2B. D. A549 cells were treated as described for 
Figure 2C. E. Cells were treated with 2 μM SAHA or 5 μM Nutlin-3A (positive control) for 24 h and then performed RT-PCR (Left) and 
qPCR (Right). F. Cells were treated with 60 nM HDAC2 siRNA or negative control siRNA for 24 h and then performed RT-PCR (Left) 
and qPCR (Right).
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cytotoxicity. In colony-forming assays, HDAC2 siRNA 
had a greater effect on IR sensitivity than negative control 
siRNA (Fig. 6B). Fig.6C showed that cleavage of caspase 
3/7 and PARP were more increased in cells treated with IR 
and HDAC2 siRNA. These results suggest that antitumor 
effect of HDAC2 targeting in lung cancer cells might be a 
apoptotic cell death induced by DNA damage. To find the 
combined effects of IR and HDAC2 siRNA treatment on 
ATM/ATR signaling, we examined the levels of phospho-
ATM/ATR, -Chk1/2, and -γH2AX after treated with IR 
or IR/HDAC2 siRNA by Western blotting. As shown in 
Fig. 6D, the phosphorylation levels of Chk2 and γH2AX 
were more increased in cells treated with IR and HDAC2 
siRNA than those in IR alone treatment. These results 
indicate that inhibition of HDAC2 by siRNA enhanced the 
cytotoxicity which is consequences of the DNA damage 
induced by IR in lung cancer cells. IR/HDAC2 siRNA-
induced cell death was restored in cells transfected with 
p53 siRNA or survivin overexpression plasmid. (Fig 6D, 
6E) These results suggest that targeting HDAC2 could 
be effective in the radiotherapy of non-small-cell lung 
cancers harboring wild-type p53. 
Figure 4: Mdm2 ubiquitination by SAHA or HDAC2 siRNA. After incubation, cells were lysed and analyzed by IP and Western 
blotting as described in Materials and Methods. β-actin was used as a control for equal protein loading. Immunoblots are representative 
of at least three independent experiments. A. A549 cells were treated with 2 μM SAHA and incubated for 6 h. After incubation, 2.5 -5 μM 
MG132 was added and cells were incubated for an additional 18 h. B. A549 cells were transfected with 60 nM HDAC2 siRNA or control 
siRNA and incubated for 6 h. After incubation, 2.5 -5 μM MG132 was added and cells were incubated for an additional 18 h. C. A549 cells 
were treated as described for Figure 4A or 4B and then immunoprecipitated using Mdm2 antibody and blotted with anti-Ubiquitin antibody. 
D. A549 cells were co-transfected with HA-Ub, Flag-Mdm2 plasmid and HDAC2 siRNA and then treated with 2 μM SAHA for 6h. After 
incubation, 5 μM MG132 was added and cells were incubated for an additional 18h. Cell lysate was subjected to IP assay using anti-Flag 
antibody and blotted with anti-HA antibody.
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Figure 5: Correlation between HDAC2 and survivin expression in lung cancer cell lines and overexpression of HDAC2 
and survivin in lung cancer patients. A. A549, H460 and Lu99 cells were lysed and lysates were analyzed by Western blotting. B. 
The expression of HDAC2 and survivin in lung cancer patient specimens (stage I-20 samples, stage II-14 samples, stage III-5 samples, and 
stage IV-1 sample) and normal lung tissue (8 samples, total 48 samples). Graphs show the quantitative data of upper bands using Image 
J program. The relative levels of HDAC2 and survivin mRNA expression in lung cancer patients compared to average of 8 normal lung 
tissues (set as 1) were represented.
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Figure 6: Effect of HDAC2 inhibition on IR-induced cell death. After incubation, cells were analyzed by MTT, Western blotting 
and colony forming assay as described in Materials and Methods. β-actin was used as a control for equal protein loading. Values were 
represented as means ± SD of three independent experiments. Immunoblots are representative of at least three independent experiments. A. 
A549 cells were transfected with 60 nM HDAC2 siRNA and then treated with IR (5 Gy) for 48 h or 72h. Cell viability was determined by 
MTT assay, as described in Materials and Methods, and expressed relative to that of controls (defined as 100%). B. A549 cells were treated 
with 60 nM HDAC2 siRNA, alone or combination with IR (1 or 2 Gy). After 18 d, colonies were stained and counted. The relative surviving 
fractions were calculated by dividing the number of colonies in treated cells by that in controls. Each value represents the mean ± S.D. of 
three independent experiments (###P < 0.001 vs. IR 2Gy-treated groups). C. A549 cells were treated as described for Figure 6A (48h). D. 
A549 cells were transfected with 60 nM HDAC2 siRNA. After 6h, then cells were treated with IR. Cells were harvested in time course. E. 
A549 cells were transfected with 50 nM p53 siRNA and 60 nM HDAC2 siRNA, alone or in combination, and then treated with IR (5Gy) 
for 72 h. Each value represents the mean ± S.D. of three independent experiments (###P < 0.001 vs. si CTL/siHDAC2/IR-treated groups). F. 
A549 cells were co-transfected 0.2 μg survivin-myc plasmid (Survivin-myc) or empty vector (mock) and 60 nM HDAC2 siRNA and then 
treated with 5Gy IR for 72 h. Each value represents the mean ± S.D. of three independent experiments (###P < 0.001 vs mock/siHDAC2/
IR-treated groups). G. A scheme shows that SAHA or HDAC2 siRNA decreased survivin level through p53-Mdm2 pathway in A549 cells. 
Downregulated survivin by SAHA or HDAC2 siRNA confers enhanced responsiveness of the cells to ionizing radiation.
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DISCUSSION
The potential role of HDAC inhibitors in 
downregulating survivin expression has been described 
previously [18-22]. SAHA, a reversible pan-inhibitor of 
HDACs, inhibits class I (1, 2, 3 and 8) and II (4, 5, 6, 
7, and 9) HDACs. Therefore, to identify which subfamily 
of HDACs is (are) involved in regulation of survivin, we 
tested several siRNAs against HDAC1, HDAC2, HDAC3 
and HDAC4. The results (Fig.2 and Fig.3) show selective 
depletion of HDAC2 dominantly mediated survivin and 
MDM2 downregulation. Individual HDACs may play 
distinct roles and contribute differently in cells. However, 
they show massive over-compensation and share the link 
in pathway. In particular, HDAC1 and HDAC2 show 
compensatory and overlapping functions so that it is 
complicated to indicate differing effects between specific 
HDAC subsets [28]. In Fig. 3B, treatment of HDAC1 
knockdown alone inhibited MDM2 to some extent. We 
thought that it seems to be a compensatory action between 
HDAC Class I. In this regards, various HDACs subfamily 
directly or indirectly seems to affect on survivin and Mdm2 
expression. In spite of such a compensation between 
HDACs, siRNA of HDAC2 dominantly downregulates 
survivin and Mdm2 expression compared with HDAC1 
or HDAC3 siRNA. Moreover, p53 expression in protein 
levels were most remarkably upregulated in cells treated 
with HDAC2 siRNA other than those of HDACs siRNA. 
These results suggest that suppression of HDAC2 
specifically induced downregulation of survivin through 
p53 activation in lung cancer cells.
Upon HDAC inhibition, p53 is stabilized and 
acetylated at lysines 320, 373, and 382 [29, 30]. The 
intracellular amount of p53 is primarily regulated by 
the Mdm2 oncoprotein through a negative feedback 
mechanism, whereby elevated levels of p53 stimulate 
the expression of Mdm2, which in turn sequesters and 
ubiquitinates p53, marking it for proteasomal degradation 
and/or nuclear exclusion [31]. Thus, Mdm2, acting 
primarily as an E3 ubiquitin ligase, is a key regulator of 
the p53 tumor suppressor, promoting its degradation and 
also inhibiting its transcriptional activity by recruiting 
histone deacetylase and corepressors to p53 [32]. In 
this context, we examined the role of Mdm2 in the p53-
mediated downregulation of survivin induced by inhibition 
of HDAC2. Interestingly, Mdm2 was downregulated 
at the protein level by the HDAC inhibitor SAHA and 
by siRNA targeting HDAC2 (Fig. 3). Consistently with 
this, ubiquitination assays confirmed that Mdm2 was 
ubiquitinated after treatment with SAHA and/or HDAC2 
siRNA. These results indicate that downregulation 
of Mdm2 by inhibition of HDAC2 occurred through 
proteasome-mediated degradation of Mdm2 protein.
It is known that Mdm2 is capable of self-
ubiquitination through its E3 ligase function [33]. To 
test whether self-ubiquitination was responsible for the 
proteosomal degradation of Mdm2 induced by HDAC2 
inhibition, we co-transfected H1299 cells with HDAC2 
siRNA and expression constructs for p53 and an E3 
ligase-deficient Mdm2 mutant. We found that Mdm2 
was decreased by HDAC2 siRNA, suggesting that 
Mdm2 self-ubiquitination is not involved in the Mdm2 
downregulation induced by HDAC2 inhibition (Data 
not shown). Thus, fully elucidating the regulation of p53 
by HDAC will require additional studies to identify the 
E3 ligase(s) responsible for Mdm2 degradation in this 
pathway. 
In this study, we found that expression levels of 
survivin were significantly correlated with HDAC2 
expression levels in p53 wild type lung cancer cell lines 
although cases are not sufficient (Fig. 5A). And survivin 
and HDAC2 expression levels are mostly overexpressed 
in cancer patients compared to normal lung tissue (Fig. 
5B). In this study, we suggest that not only survivin 
downregulation plays an important role in HDAC2 
inhibition-induced cell death, but targeting of the HDAC2 
and survivin is the cancer selective treatment. Survivin 
is rarely present in normal tissue or cells. Increased 
expression of survivin and HDAC2 are detected in cancer 
cells including lung cancer [13]. In addition, normal 
cells are relatively resistant to HDAC inhibitor-induced 
cell death [8]. HDAC inhibitor can alter the structure 
and function of a broad range of proteins regulating cell 
proliferation, migration, and death that are substrates of 
HDACs. Cancer cells generally have multiple defects in 
proteins regulating cell proliferation, cell migration, and 
cell death. Thus, cancer cell may have less capacity to 
compensate for the HDAC inhibitor effects than normal 
cells [28]. 
In Fig. 6D, Chk2 phosphorylation is known to be 
occurred by ATM dependent manner in response to IR 
[Ref.2], however, phospho-Chk2 was more increased in 
cells combination treated with IR and HDAC2 siRNA 
than those in IR alone treatment, ATM-independently. 
Therefore, selective depletion of HDAC2 would be 
sufficient to potentiate Chk2 phosphorylation and 
confer sensitivity to DNA damage. Although further 
study is needed to identify the factor responsible for 
phosphorylation of Chk2 induced by inhibition of HDAC2, 
our study may provide insight into the mechanism by 
which HDAC inhibitors potentiate radiotherapy and may 
provide guidance in the further development of therapeutic 
agents that more selectively inhibit HDAC2.
In conclusion, Fig. 6F depicts our proposed scheme 
in which SAHA or HDAC2 siRNA treatment of lung 
cancer cells results in Mdm2 downregulation and p53 
activation, consequently downregulation of survivin. 
Downregulation of survivin enhances the responsiveness 
of the cells to ionizing radiation, then rendering the tumor 
cells less resistant to ionizing radiation-induced cell death.
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MATERIAL AND METHODS
Cell cultures and reagents
A549, H1299 and H460 human lung cancer cells 
purchased from the American Type Culture Collection 
(Manassas, VA, USA), Lu99 human lung cancer cells, 
purchased from the RIKEN cell bank (Tsukuba, Japan), 
and HCT 116 colorectal cancer cells (p53 null and p53 
wild) were supplied by Dr. Kee-Ho Lee (KIRAMS, 
KOREA) were grown in the recommended growth 
medium (Invitrogen, Carlsbad, CA, USA). SAHA 
was purchased from ALEXIS Corporation (Lausen, 
Switzerland). Antibodies against HDAC1, HDAC2, 
HDAC3, cIAP2, Mdm2, HA, Myc and β-actin were 
acquired from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). HDAC4, SIRT1, SIRT2, histone 3, acetyl-histone 
3, acetyl-histone 4, acetyl-p53 (Lys382), puma, ubiquitin, 
caspase 3, cleaved PARP, p-ATM, ATM, p-ATR, ATR, 
p-Chk1, Chk1, p-Chk2, Chk2, p-γH2AX, γH2AX and 
survivin antibodies were acquired from Cell Signaling 
Technology (Beverly, MA, USA). XIAP, caspase 7 and 
p21 antibodies were purchased from BD Biosciences 
Pharmingen (San Diego, CA, USA), and the p53 antibody 
was from Novocastra Lab. Ltd. (Newcastle, UK). The 
Flag antibody, Nutlin-3A and MG132 were from Sigma. 
(St Louis, MO, USA). The siRNAs targeting HDAC1, 
HDAC2, HDAC3, or HDAC4 were from Santa Cruz 
Biotechnology. Two different HDAC2 siRNAs (siHDAC 
#2 and siHDAC #3) and p53-specific siRNA were 
purchased from Ambion (Austin, TX, USA). 
Transfections and treatments
A549 cells in 1 ml of serum-free medium were 
transfected with plasmid (0.1-0.2μg) or siRNA (50-
120 nM) for 4 h at 37°C in a CO2 incubator using 
Lipofectamine (Invitrogen) as described by the 
manufacturer. The media were then replaced with fresh 
media containing 10% fetal bovine serum and cells were 
incubated for an additional 2 h. After transfection, cells 
were treated with SAHA and/or IR and analyzed as 
described below. The cells were irradiated using a 137Cs 
γ-ray source (Atomic Energy of Canada Ltd., Canada). 
Reverse transcription-polymerase chain reaction 
(RT-PCR)
Total RNA was isolated using a RNA mini kit 
(Qiagen, Valencia, CA, USA). An aliquot of total RNA (2 
μg) was transcribed into cDNA using an RT2 First Strand 
kit (Qiagen). cDNA was amplified with Taq polymerase 
(Promega, Madison, WI, USA) using the specific primer 
pairs (Santacruz) for conventional PCR. For qPCR, cDNA 
was amplified with a KAPA SYBR FASR qPCR kit (Kapa 
Biosystems, Woburn, MA, USA) using the specific primer 
pairs (Origene Technologies, Rockville, MD, USA). 
HDAC2 and survivin mRNA expression levels 
in lung cancer patient tissue were analyzed using a 
TissueScan Cancer Array from Origene Technologies, 
according to the manufacturer’s protocols. In brief, after 
aliquot 25 μL of the PCR pre-mix including β-actin or 
HDAC2 specific primer pairs to each well (Tissue cDNAs 
of each array are synthesized from high quality total RNAs 
of pathologist-verified tissues), the thermocycling was 
performed. The condition was followed: pre-soak 95 °C 
for 10 min and 39 cycles of 95°C for 15 s, 60°C for 20 s.
Western blotting
Cells were harvested and lysed in RIPA buffer (50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet P40, 
0.5% sodium deoxycholate, and 0.1% SDS) supplemented 
with a protease/phosphatase inhibitor cocktail (Roche, 
Mannheim, Germany). Equal amounts of protein (20-50 
μg) were separated by SDS-PAGE and transferred to a 
nitrocellulose membrane. Membranes were blocked by 
incubating with 3% skim milk in Tris-buffered saline 
(TBS) for 1 h and then were incubated overnight with the 
appropriate primary antibodies (1000:1). Membranes were 
then incubated with HRP-conjugated secondary antibody 
(3000:1) for 1 h. Immunoreactive proteins were visualized 
using enhanced chemiluminescence reagents (Amersham 
Biosciences, Little Chalfont, UK).
Measurement of cell viability
Cell viability was determined by measuring the 
mitochondrial conversion of 3-(4,5-dimethylthiazolyl-
2)-2,5-diphenyltetrazolium bromide (MTT) to a colored 
product. Cells were treated as indicated, and the medium 
was exchanged with serum-free medium containing 1 
mM MTT. After 2 h of incubation at 37°C, cells were 
solubilized in DMSO. The amount of formazan, the 
converted form of MTT, was determined by measuring 
absorbance at 595 nm.
Clonogenic assay
Cells were transfected with 60 nM siRNA and 
incubated for 24 h. Transfected cells were seeded at a 
concentration of 300-500 cells/60-mm dish. After 24 h, 
cells were irradiated with different doses (1 or 2 Gy) of 
IR (γ-irradiation). After culturing for 18 d, colonies were 
stained using a Diff Quik kit (Sysmex, Kobe, Japan), and 
the number of colonies greater than 2 mm in diameter 
were counted. The surviving fraction was calculated by 
Oncotarget26539www.impactjournals.com/oncotarget
dividing the number of colonies in treated cell groups by 
that in the control group. 
Ubiquitination assay
Cells were lysed in lysis buffer (20 mM Tris pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton 
X-100 and protease/phosphatase inhibitor cocktail) and 
centrifuged at 12000 rpm for 20 min. Cell lysates were 
immunoprecipitated using an anti-Mdm2 or anti-Flag 
antibodies and protein A/G agarose beads overnight 
at 4°C. The beads were washed with Tris-Cl buffer 
and boiled in 2x SDS sample buffer. Proteins in the 
supernatant were separated by SDS-PAGE and analyzed 
by immunoblotting using an anti-ubiquitin or anti-HA 
antibodies as described [23]. 
Statistical Analysis
P values were calculated by applying the two-tailed 
Student’s test to data from independent experiments. 
Quantitative data are presented as means ± standard 
deviation (SD).
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